Scientific interests:
Clinical trials and drug development in psychiatry
Academic Education:
1999 to 2006
Diploma program Biology, RWTH Aachen
(Diploma thesis: Investigation of auditory post-effects in screech owl (Tyto alba)).
(Diploma thesis: Investigation of auditory post-effects in screech owl (Tyto alba)).
2006 to 2012
PhD student, University of Cologne
Research Group Experimental and clinical Neuropsychopharmacology
in cooperation with Max-Planck-Institut for neurological research.
Research Group Experimental and clinical Neuropsychopharmacology
in cooperation with Max-Planck-Institut for neurological research.
Doctoral thesis (Ph.D.):
2012
"Investigation of behavioral pharmacology and brain metabolism during acut and chronic modulation of the endocannabinoid system in rats."
University of Cologne, Faculty of Mathematics and Natural Sciences
University of Cologne, Faculty of Mathematics and Natural Sciences
Professional activity:
2006 to 2009
Postgraduate student (PhD), Dept. of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany
2009 to 2012
Postgraduate student (PhD), Central Institute of Mental Health, Mannheim, Germany
since 2012
Associated Researcher, Institute of Radiochemistry and Experimental Molecular Imaging,
Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
2012 to 2018
Post doc, Central Institute of Mental Health, Mannheim, Germany
since 2018
Associated Researcher, Research Group Translational Research in Psychiatry,
Dept. of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany
Dept. of Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany
2018 to 2020
Research Administration Manager and Research Fellow, Brain and Mind Centre, The University of Sydney, Sydney, Australia
since 2020
Associated Research Fellow, Brain and Mind Centre, The University of Sydney, Sydney, Australia
since 2021
since 2021
Publications:
ORCID iD:
https://orcid.org/0000-0002-3559-1846- M. Allwright, B. Guennewig, A. Hoffmann, C. Rohleder, B. Jieu, L. H. Chung, Y. C. Jiang, B. F. Lemos Wimmer, Y. Qi, A. S. Don, F. M. Leweke, T. A. Couttas (2024) ReTimeML: A retention time predictor that supports the LC-MS/MS analysis of sphingolipids. Sci Rep, in press
- I. Dammann, C. Rohleder*, F. M. Leweke* (2024) Cannabidiol and its potential evidence-based psychiatric benefits - A critical review. Pharmacopsychiatry 56:1-18
- I. B. Hickie, F. Iorfino, C. Rohleder, Y. J. C. Song, A. Nichles, N. Zmicerevska, W. Capon, A. J. Guastella, F. M. Leweke, J. Scott, P. McGorry, C. Mihalopoulos, M. K. Chong, S. Mckenna, M. Aji, C. Gorban, J. J. Crouse, D. Koethe, R. Battisti, B. Hamilton, M. Hackett, D. Hermens, Mind Plasticity Consortia, E. M Scott: The EMPOWER trial: Protocol for a randomised control trial of digitally supported, highly personalised and measurement-based care to improve functional outcomes in young people with mood disorders. BMJ Open, in press
- D. Koethe, C. Rohleder, L. Kracht, F. M. Leweke (2023) Cannabidiol enhances cerebral glucose utilisation and ameliorates psychopathology and cognition: a case report in a clinically high-risk mental state. Front Psychiatry 14:1088459
- T. A. Couttas, B. Jieu, C. Rohleder, F. M. Leweke (2022) Mini Review: Current state of fluid lipid biomarkers for personalized diagnostics and therapeutics in schizophrenia spectrum disorders and related psychoses, Front Psychiatry 13:885904
- T. A. Couttas, C. Boost, F. Pahlisch, E. B. Sykorova, D. Koethe, J. E. Leweke, H. Endepols, C. Rohleder, F. M. Leweke (2022) Simultaneous assessment of serum levels and pharmacologic effects of cannabinoids on endocannabinoids and N-acylethanolamines by liquid chromatography – tandem mass spectrometry. Cannabis Cannabinoid Res 8:657-669
- R. B. Banati, C. Rohleder, F. M. Leweke, N. Mueller, A. Sawa, R. H. Yolken, I. B. Hickie (2022) Editorial: Immune Associated Mental Illnesses in Adolescents and Young Adults: Pathophysiological Role and Therapeutic Perspectives. Front Psychiatry 13:871719
- M. W. Meinhardt, S. Pfarr, G. Fouquet, C. Rohleder, M. L Meinhardt, J. Barroso-Flores, R. Hoffmann, J. Jeanblanc, E. Paul, K. Wagner, A. C. Hansson, G. Kohr, N. Meier, O. Von Bohlen und Halbach, R. L. Bell, H. Endepols, R. Neumaier, K. Schwing, D. Bartsch, M. Naassila, R. Spanagel, W. H. Sommer (2021) Psilocybin targets a common molecular Mechanism for cognitive impairment and increased craving in alcoholism. Sci Adv 7:eabh2399
- A. Nichles, N. Zmicerevska, Y. J. C. Song, C. Wilson, C. McHugh, B. Hamilton, J. Crouse, C. Rohleder, J. S. Carpenter, N. Ho, D. F. Hermens, N. Wray, J. Scott, K. R. Merikangas, F. M. Leweke, D. Koethe, F. Iorfina, S. L. Naismith, A. J. Guastella, E. M. Scott, I. B. Hickie (2021) Neurobiology Youth Follow-up Study: protocol to establish a longitudinal and prospective research database using multimodal assessments for current and past mental health treatment-seeking young people within an early intervention service. BMJ Open 2021;11:e044731
- A. Moldavski, H. Wenz, B. Lange, C. Rohleder, F. M. Leweke (2021) Case Report: Severe adolescent major depressive syndrome turns out to be an unusual case of Anti-NMDA receptor encephalitis. Front Psychiatry 12: 679996
- F. M. Leweke, C. Rohleder, C. W. Gerth, M. Hellmich, R. Pukrop, D. Koethe (2021) Cannabidiol and amisulpride improve cognition in acute schizophrenia in an explorative, double-blind, active-controlled randomized clinical trial. Front Pharmacol 12:614811
- C. G. Bien, C. Rohleder, J. E. Mueller, C. I. Bien, D. Koethe, F. M. Leweke (2021) Neural autoantibodies in cerebrospinal fluid and serum in clinical high risk for psychosis, first-episode psychosis, and healthy volunteers. Front Psychiatry 12:654602
- D. C. Schroeder, E. Popp, C. Rohleder, S. Vus, D. P. Bethencourt, S. R. Finke, B. D. Zlatopolskiy, J. Zischler, A. Drzezga, H. Herff, T. Annecke, T. Hucho, B. Neumaier, B. W. Bottiger, H. Endepols (2021) Positron Emission Tomography Imaging of Long-Term Expression of the 18 kDa Translocator Protein After Sudden Cardiac Arrest in Rats. Shock 55(5):620-629
- A. M. Tickell, C. Rohleder, Y. J. C. Song, J. S. Carpenter, K. Harel, L. Parker, I. B. Hickie, E. Scott (2021) Protocol for a sound adult mental health (Uspace) cohort: personalising multidimensional care in young people admitted to hospital. BMJ Open 11:e038787
- T. Woelfl, C. Rohleder, J. K. Mueller, B. Lange, A. Reuter, A. M. Schmidt, D. Koethe, M. Hellmich, F. M. Leweke (2020) Effects of cannabidiol and delta-9-tetrahydrocannabinol on emotion, cognition and attention: A double-blind, placebo-controlled, randomized experimental trial in healthy volunteers. Front Psychiatry 11:576877
- C. Rohleder, Y. J. C. Song, J. J. Crouse, T. A. Davenport, F. Iorfino, B. Hamilton, N. Zmicerevska, A. Nichles, J. S. Carpenter, A. M. Tickell, C. Wilson, S. P. Cross, A. J. Guastella, D. Koethe, F. M. Leweke, E. M. Scott, I. B. Hickie (2020) Youth Mental Health Tracker: protocol to establish a longitudinal cohort and research database for young people attending Australian mental health services. BMJ Open 10:e035379
- V. L. Chadwick, C. Rohleder, D. Koethe, F. M. Leweke (2020) Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans. Current Opinion in Psychiatry 33:20-42
- Y. Bouter, M. M. Brzózka, R. Rygula, F. M. Leweke, U. Havemann-Reinecke*, C. Rohleder* (2019) Chronic psychosocial stress causes increased anxiety-like behavior and alters endocannabinoid levels in the brain in C57Bl/6J mice. Cannabis Cannabinoid Res 5:51-61
- F. Iorfino, J. S. Carpenter, S. P. Cross, T. A. Davenport, D. F. Hermens, A. J. Guastella, C. Rohleder, J. J. Crouse, F. M. Leweke, D. Koethe, S. L. Naismith, E. M. Scott, I. B. Hickie (2019) Multidimensional outcomes in youth mental health care: what matters and why? Med J Australia 211S9:S4-S11
- J. S. Carpenter, F. Iorfino, S. P. Cross, T. A. Davenport, D. F. Hermens, C. Rohleder, J. J. Crouse, F. M. Leweke, D. Koethe, A. J. Guastella, S. L. Naismith, J. Scott, E. M. Scott, I. B. Hickie (2019) Clinical staging pathophysiological mechanisms and illness trajectories in young people with emerging mental illness. Med J Australia 211S9:S12-S22
- J. J. Crouse, C. Rohleder, J. S. Carpenter, F. Iorfino, A. M. Tickell, S. P. Cross, T. A. Davenport, D. F. Hermens, A. J. Guastella, F. M. Leweke, D. Koethe, S. L. Naismith, E. M. Scott, I. B. Hickie (2019) Comprehensive assessment in young people: Guiding measurement-based care with multidimensional and objective assessments. Med J Australia 211S9:S23-S31
- C. Rohleder, J. J. Crouse, J. S. Carpenter, F. Iorfino, S. P. Cross, T. A. Davenport, D. F. Hermens, A. J. Guastella, F. M. Leweke, D. Koethe, S. L. Naismith, E. M. Scott, I. B. Hickie (2019) Personalising care options in youth mental health: using multidimensional assessment, clinical stage, pathophysiological mechanisms, and individual illness trajectories to guide treatment selection. Med J Australia 211S9: S32-S41
- C. Rohleder, F. Pahlisch, R. Graf, H. Endepols, F. M. Leweke (2019) Differential pharmaceutical preparations of ∆-9-tetrahydrocannabinol differentially affect its behavioral effects in rats. Addict Biol 25:e12745
- D. Koethe*, F. Pahlisch*, M. Hellmich*, C. Rohleder, C. Hoyer, A. Meyer-Lindenberg, E. F. Torrey, D. Piomelli, F. M. Leweke (2019) Familial abnormalities of endocannabinoid signalling in schizophrenia. World J Biol Psychiatry 20:117-125
- F. M. Leweke*, J. K. Mueller*, B. Lange, S. Fritze, C. E. Topor, D. Koethe, C. Rohleder (2018) Role of the endocannabinoid system in the pathophysiology of schizophrenia: Implications for pharmacological interventions. CNS Drugs 32:605-619
- O. Grimm, M. Löffler, S. Camping, C. Rohleder, F. M. Leweke, H. Flor (2018) Probing the endocannabinoid system in healthy volunteers: cannabidiol alters fronto-striatal resting-state connectivity. Eur Neuropsychopharmacol 28:841-849
- F. M. Leweke, C. Rohleder, J. K. Mueller, D. Hirjak, A. Meyer-Lindenberg (2018) Cannabidiol zur Verbesserung der Genesung in frühen Stadien einer Schizophrenie. Eine randomisierte, kontrollierte klinische Prüfung der adjuvanten Gabe zur individuellen antipsychotischen Behandlung. Nervenheilkunde 37:1-4
- C. Rohleder*, D. Koethe*, S. Fritze, C. E. Topor, F. M. Leweke, D. Hirjak (2018) Neural correlates of binocular depth inversion illusion in antipsychotic-naïve first-episode schizophrenia patients. Eur Arch Psychiatry Clin Neurosci DOI 10.1007/s00406-018-0886-2
- A. R. Reuter*, J. M. Bumb*, J. K. Mueller*, C. Rohleder, F. Pahlisch, F. Hanke, E. Arens, F. M. Leweke, D. Koethe, E. Schwarz (2017) Association of anandamide with altered binocular depth inversion illusion in schizophrenia. World J Biol Psychiatry 18:483-48
- C. Rohleder, J. K. Mueller, B. Lange, F. M. Leweke (2016) Cannabidiol as a potential new type of an antipsychotic: a critical review of the evidence. Front Pharmacol 7:422
- C. Rohleder, D. Wiedermann, B. Neumaier, A. Drzezga, L. Timmermann, R. Graf, F. M. Leweke, Heike Endepols (2016) The functional networks of prepulse inhibition: Neuronal connectivity analysis based on FDG-PET in awake and unrestrained rats. Front Behav Neurosci 10:148
- F. M. Leweke, J. K. Mueller, B. Lange, C. Rohleder (2016) Therapeutic potential of cannabinoids in psychosis. Biol Psychiatry 79:604-612
- J. K. Mueller, C. Rohleder, F. M. Leweke (2016) What is the promise of nicotinergic compounds in schizophrenia treatment? Future Med Chem 8:2009-201
- E. G. Severance, K. L. Gressitt, A. Alaedini, C. Rohleder, F. Enning, J. M. Bumb, J. K. Mueller, E. Schwarz, R. H. Yolken, F. M. Leweke (2015) IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia. Brain Behav Immun 44, 148-58.
- M. Grosshans, E. Schwarz, J. M. Bumb, C. Schaefer, C. Rohleder, C. Vollmert, S. Vollstadt-Klein, H. Tost, A. Meyer-Lindenberg, F. Kiefer, F. M. Leweke (2014) Oleoylethanolamide and human neural responses to food stimuli in obesity. JAMA Psychiatry 71, 1254-61
- C. Rohleder, F. Jung, H. Mertgens, D. Wiedermann, M. Sue, B. Neumaier, R. Graf, F. M. Leweke, H. Endepols (2014) Neural correlates of sensorimotor gating: a metabolic positron emission tomography study in awake rats. Front Behav Neurosci 8, 178
- C. Schaefer, F. Enning, J. K. Mueller, J. M. Bumb, C. Rohleder, T. M. Odorfer, J. Klosterkotter, M. Hellmich, D. Koethe, C. Schmahl, M. Bohus, F. M. Leweke (2014) Fatty acid ethanolamide levels are altered in borderline personality and complex posttraumatic stress disorders. Eur Arch Psychiatry Clin Neurosci 264:459-463.
- European Network of National Networks studying Gene-Environment Interactions in, J. van Os, B. P. Rutten, I. Myin-Germeys, P. Delespaul, W. Viechtbauer, C. van Zelst, R. Bruggeman, U. Reininghaus, C. Morgan, R. M. Murray, M. Di Forti, P. McGuire, L. R. Valmaggia, M. J. Kempton, C. Gayer-Anderson, K. Hubbard, S. Beards, S. A. Stilo, A. Onyejiaka, F. Bourque, G. Modinos, S. Tognin, M. Calem, M. C. O'Donovan, M. J. Owen, P. Holmans, N. Williams, N. Craddock, A. Richards, I. Humphreys, A. Meyer-Lindenberg, F. M. Leweke, H. Tost, C. Akdeniz, C. Rohleder, J. M. Bumb, E. Schwarz et al. (2014) Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull 40, 729-36.
- L. N. Hayes, E. G. Severance, J. T. Leek, K. L. Gressitt, C. Rohleder, J. M. Coughlin, F. M. Leweke, R. H. Yolken, A. Sawa (2014) Inflammatory molecular signature associated with infectious agents in psychosis. Schizophr Bull 40, 963-72.